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The interest in the use of non-catecholamine vaso-
pressors for the treatment of hypotension and shock
has increased in recent years. The use of vasopres-
sin as an adjunctive vasopressor in shock was
reinvigorated by Landry and colleagues [1] and then
carefully assessed in the Vasopressin versus Nor-
epinephrine Infusion in Patients with Septic Shock
(VASST) trial [2]. In a large, international, multi-
center trial, vasopressin demonstrated a satisfactory
safety profile, but did not show an improvement in
survival compared to norepinephrine [2]. In addition
to vasopressin, angiotensin II (ATII) has been pro-
posed as a useful vasopressor for the management
of shock [3, 4]. The original studies that assessed
ATII for the management of shock were conducted
decades ago [3, 5]. In those trials, ATII was
assessed primarily in head-to-head studies compared
to catecholamine vasopressors, and was shown to
have comparable vasopressor effect to norepineph-
rine [5]. Multiple case reports demonstrated the
ability of ATII to work effectively as a vasopressor
and also showed that ATII could be used in com-
bination with catecholamines. However, ATII has
not been subjected to a randomized controlled trial
(RCT) and ATII has not been available at the bed-
side for at least 15 years. ATII has been used ex-
tensively in physiology, hypertension, cancer, and
pregnancy studies in humans and has a good safety
profile.
Recently, we published in Critical Care the first
RCT of ATII in patients with distributive shock, and
showed that a dose of ATII of 5–40 ng/kg/min was
associated with improved blood pressure that resulted
in significant catecholamine sparing [6]. In that
modest-sized study, we noted that 2 of the 10 pa-
tients treated with ATII were exquisitely sensitive to
ATII. In these two cases, the subjects receiving
physiologic doses of ATII were hypertensive despite
the discontinuation of their norepinephrine. When
ATII was stopped in these two patients, re-initiation
of a high dose of norepinephrine (i.e., 0.3 μg/kg/min)
was immediately required in order to maintain mean
arterial pressure goals. We speculated that the reason
for this sensitivity was likely due to premorbid expos-
ure to angiotensin-converting enzyme (ACE) inhibi-
tors prior to the development of shock. Our theory
was that if the subjects were previously treated with
ACE inhibitors, their ATII Type I receptors would be
upregulated, thus making the patient more sensitive
to exogenous ATII infusion. However, after a thor-
ough chart review and re-review, we could not docu-
ment an ACE inhibitor exposure. While it is possible
that the ACE inhibitor exposure was present and not
documented, there is an alternative explanation which
is related to the nature and distribution of ACE.
Angiotensin I (ATI) is converted efficiently to ATII
almost exclusively in the lung [7]. ACE is an ectoen-
zyme which is distributed primarily on the pulmonary
capillary endothelium [8, 9]. As a consequence, dis-
eases that affect the pulmonary capillary endothelium
can disrupt ACE functionality. Acute respiratory dis-
tress syndrome (ARDS) is often associated with sig-
nificant pulmonary endothelial injury [10]. Patients
with more severe ARDS have less capacity to convert
angiotensin ATI to ATII, and this disturbance is in-
versely correlated to the severity of ARDS [11]. Upon
re-review, we found that the two patients in our
study who were exquisitely ATII sensitive had severe
ARDS.
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Our revised hypothesis is that patients with severe
ARDS may have significant pulmonary endothelial
injury, which results in either an absolute or relative
insufficiency of ATII due to loss of pulmonary ACE.
Pre-clinical and human case reports demonstrate
that when ATII production is inhibited by ACE in-
hibition, patients become catecholamine resistant
[12]. Thus, patients with ARDS may be at particular
risk for ATII insufficiency, which would likely ex-
acerbate existing hypotension. In addition, ATII in-
sufficiency can lead to acute kidney injury due to
decreased intra-glomerular pressure. We hypothesize
that some patients with shock and ARDS may be at
particular risk for a deleterious cascade of events re-
lated to ATII insufficiency (Fig. 1).
We would anticipate that, for those patients with
ATII insufficiency, increased levels of ATI and re-
duced ATII may be indicative of this pathophysiology,
and that ATI and ATII levels, as well as the ratio of
ATI/ATII, may be useful as biomarkers of early ARDS
or ARDS severity prior to the development of severe
hypoxemia. Moreover, we would anticipate these pa-
tients to be ATII-sensitive. We believe that further re-
search to test this hypothesis is warranted. Currently,
ATII is being studied in a multi-center international
RCT (NCT02338843) wherein some of these parame-
ters will be assessed and may shed further light on
this proposed hypothesis.
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Fig. 1 Proposed cascade of events leading to angiotensin II insufficiency. The figure outlines a cascade of events that could occur amongst
patients with inflammation and/or lung injury. When acute lung injury is significantly complicated by pulmonary endothelial injury, ACE activity is
diminished [11]. Thus, patients who lose ACE activity may be a risk for angiotensin II insufficiency and catecholamine resistance [12]. ACE
angiotensin-converting enzyme, ARDS acute respiratory distress syndrome, PCE pulmonary capillary endothelium
Chawla et al. Critical Care  (2016) 20:137 Page 2 of 3
9. Cziraki A, Horvath I, Rubin JW, Theodorakis M, Catravas JD. Quantification of
pulmonary capillary endothelium-bound angiotensin converting enzyme
inhibition in man. Gen Pharmacol. 2000;35(4):213–8.
10. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J
Med. 2000;342(18):1334–49.
11. Orfanos SE, Armaganidis A, Glynos C, Psevdi E, Kaltsas P, Sarafidou P, et al.
Pulmonary capillary endothelium-bound angiotensin-converting enzyme
activity in acute lung injury. Circulation. 2000;102(16):2011–8.
12. Correa TD, Jeger V, Pereira AJ, Takala J, Djafarzadeh S, Jakob SM.
Angiotensin II in septic shock: effects on tissue perfusion, organ function,
and mitochondrial respiration in a porcine model of fecal peritonitis.
Crit Care Med. 2014;42(8):e550–9.
Chawla et al. Critical Care  (2016) 20:137 Page 3 of 3
